10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...

BofA analyst Michael Ryskin lowered the firm’s price target on 10x Genomics (TXG) to $12 from $16 and keeps a Neutral rating on the shares.

Founded in 2012, 10x Genomics (NASDAQ:TXG ... We introduced a new microfluidic architecture, GEM-X and a slate of new products and capabilities. Once again, we raised the bar on performance ...

The Genomics Core houses a 10X Genomics Chromium iX which has the capacity to prepare GEMs for all standard 10X Genomics single cell pipelines: 3" scRNAseq single cell immune profiling fixed RNA ...

PLEASANTON, Calif., April 14, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced it will report financial results for the first quarter ...

Barclays analyst Luke Sergott lowered the firm’s price target on 10x Genomics (TXG) to $12 from $15 and keeps an Overweight rating on the ...

Our facility is equipped with state-of-art instruments, including the 10X Genomics Chromium X which enables high-throughput single cell gene expression profiling, 10X Genomics Xenium platform, and the ...

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...

10x Genomics reported revenues of $165 million ... Want to invest in winners with rock-solid fundamentals? Check out our ...